1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
(
- Contribution to journal › Article
- 2020
-
Mark
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour : A Population-based Study from the Swedish Norwegian Testicular Cancer Group
(
- Contribution to journal › Article
-
Mark
Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh : A Randomised Study
(
- Contribution to journal › Article
- 2019
-
Mark
Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations : effect of a prospective intervention in primary bladder cancer patients
(
- Contribution to journal › Article
- 2017
-
Mark
Diagnosing Distal Urethral Carcinomas in Men Might Be Only the Tip of the Iceberg
(
- Contribution to journal › Article
- 2016
-
Mark
The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway
(
- Contribution to journal › Article
-
Mark
Penile cancer in Scandinavia: Current practice and future perspectives
(
- Contribution to journal › Letter
-
Mark
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy : A report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
(
- Contribution to journal › Article
- 2015
-
Mark
Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols
(
- Contribution to journal › Article
- 2014
-
Mark
One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.
(
- Contribution to journal › Article